In the DAPA-HF trial, there was a notable 30% reduction in worsening heart failure events among patients receiving the SGLT-2 inhibitor as part of their treatment (10.0 vs 13.7%; HR 0.70; 95% CI: 0.59-0.83; p<0.00004) and 18% reduction in cardiovascular mortality (9.6 vs 11.5%; HR: 0.82; 95% CI: 0.69-0.98; p=0.029). The gene discussed is SLC5A2; the disease is heart failure.